

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	9	erythropoietin near5 administering and 530/350.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 16:15
L2	39	erythropoietin near5 administering and 514/12.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 16:15
L3	11	erythropoietin near5 administering and 435/69.1.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 16:16
L4	1	erythropoietin near5 administering and 435/7.1.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 16:16
S1	5307	E1A	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:15
S2	4776	E1A and protein	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:16
S3	2598	E1A same protein	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:16
S4	1894	E1A with protein	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:16
S5	697	"E1A protein"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:16
S6	690	"E1A protein" and adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:16
S7	601	"E1A protein" same adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:17

EAST Search History

S8	540	"E1A protein" with adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:17
S9	0	"E1A protein with adenovirus"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:17
S10	65	"E1A protein adenovirus"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:21
S11	458014	"E1A protein adenovirus" and cell expression	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:18
S12	60	"E1A protein adenovirus" and cell with expression	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:18
S13	17	"E1A protein adenovirus" same cell with expression	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:20
S14	11	"E1A protein adenovirus" and erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:24
S15	3	"E1A protein adenovirus" same erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:21
S16	5662	E1A protein adj adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:23
S17	65	E1A adj protein adj adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:23
S18	108	E1A adj protein adj5 adenovirus	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:23
S19	15094	erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:24

EAST Search History

S20	8088	erythropoietin and administering	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:24
S21	611	erythropoietin same administering	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:24
S22	10	erythropoietin adj administering	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:25
S23	49	erythropoietin near administering	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:26
S24	171	erythropoietin near5 administering	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 16:15
S25	2	erythropoietin near5 administering and chronic adj coronary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:31
S26	33	erythropoietin near5 administering and coronary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/13 16:31
S27	0	"6351121".ap. and vascular	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:26
S28	0	"6351121".ap. and coronary	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:36
S29	0	"6351121".ap. and myocardial	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S30	0	"6351121".ap. and heart with disease	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:37
S31	0	"6351121".ap. and heart	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:37

EAST Search History

S32	0	"6351121".ap.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:37
S33	0	"6351121".pn. and myocardial	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S34	2	"6351121".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S35	1	"6351121".pn. and heart	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S36	0	"6351121".pn. and heart with disease	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S37	1	"6351121".pn. and heart	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S38	2	"6531121".pn. and heart	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:38
S39	1	"6531121".pn. and heart with disease	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:39
S40	2	"6531121".pn. and myocardial	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:40
S41	28911	"6531121".pn. and myocardial amd erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:41
S42	2	"6531121".pn. and myocardial and erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:42
S43	1	"6531121".pn. and myocardial same erythropoietin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/07/19 13:42

FILE 'HOME' ENTERED AT 14:59:58 ON 19 JUL 2006

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:00:24 ON 19 JUL 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> erythropoietin and administering

6	FILE ADISCTI
3	FILE ADISINSIGHT
4	FILE BIOENG
36	FILE BIOSIS
194	FILE BIOTECHABS
194	FILE BIOTECHDS
28	FILE BIOTECHNO
2	FILE CABA
150	FILE CAPLUS
1	FILE CIN
6	FILE DDFU
884	FILE DGENE
13	FILE DRUGU
1	FILE EMBAL
61	FILE EMBASE
11	FILE ES BIOBASE

34 FILES SEARCHED...

1	FILE GENBANK
1	FILE HEALSAFE
781	FILE IFIPAT
1	FILE IMSDRUGNEWS
5	FILE IMSRESEARCH
9	FILE JICST-EPLUS
5	FILE LIFESCI
59	FILE MEDLINE
19	FILE PASCAL
12	FILE PHIN
25	FILE PROMT
41	FILE SCISEARCH
102	FILE TOXCENTER
7115	FILE USPATFULL
697	FILE USPAT2
1	FILE VETU
418	FILE WPIDS
5	FILE WPIFV
418	FILE WPINDEX

35 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE ERYTHROPOIETIN AND ADMINISTERING

=> erythropoietin with administering

2	FILE BIOTECHABS
2	FILE BIOTECHDS
1	FILE CAPLUS

```

23 FILES SEARCHED...
    12  FILE IFIPAT
44 FILES SEARCHED...
48 FILES SEARCHED...
    14  FILE USPATFULL
     1  FILE USPAT2
     2  FILE WPIDS
     2  FILE WPINDEX

    8 FILES HAVE ONE OR MORE ANSWERS,    68 FILES SEARCHED IN STNINDEX

L2  QUE ERYTHROPOIETIN WITH ADMINISTERING

=> erythropoietin adj5 administering
    42 FILES SEARCHED...

    0 FILES HAVE ONE OR MORE ANSWERS,    68 FILES SEARCHED IN STNINDEX

L3  QUE ERYTHROPOIETIN ADJ5 ADMINISTERING

=> erythropoietin near administering
    33 FILES SEARCHED...

    0 FILES HAVE ONE OR MORE ANSWERS,    68 FILES SEARCHED IN STNINDEX

L4  QUE ERYTHROPOIETIN NEAR ADMINISTERING

=> erythropoietin (p) administering
     1  FILE ADISCTI
     2  FILE ADISINSIGHT
    0*  FILE ADISNEWS
    0*  FILE ANTE
    0*  FILE AQUALINE
     4*  FILE BIOENG
    33  FILE BIOSIS
   194*  FILE BIOTECHABS
   194*  FILE BIOTECHDS
    28*  FILE BIOTECHNO
     1  FILE CABA
    56  FILE CAPLUS
    0*  FILE CEABA-VTB
     1*  FILE CIN
     5  FILE DDFU
   857  FILE DGENE
    12  FILE DRUGU
     1  FILE EMBAL
    39  FILE EMBASE
   11*  FILE ES BIOBASE
    0*  FILE FOMAD
    0*  FILE FOREGE
    0*  FILE FROSTI
    0*  FILE FSTA
34 FILES SEARCHED...
     1  FILE GENBANK
     1  FILE HEALSAFE
   667  FILE IFIPAT
     1  FILE IMSDRUGNEWS
     5  FILE IMSRESEARCH
     7  FILE JICST-EPLUS
    0*  FILE KOSMET
     5  FILE LIFESCI
    47  FILE MEDLINE
    0*  FILE NTIS
    0*  FILE NUTRACEUT

```

19* FILE PASCAL
 0* FILE PHARMAML
 7 FILE PHIN
 8 FILE PROMT
 25 FILE SCISEARCH
 43 FILE TOXCENTER
 499 FILE USPATFULL
 54 FILE USPAT2
 1 FILE VETU
 0* FILE WATER
 275 FILE WPIDS
 2 FILE WPIFV
 275 FILE WPINDEX

35 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L5 QUE ERYTHROPOIETIN (P) ADMINISTERING

=> erythropoietin with administering

2 FILE BIOTECHABS
 2 FILE BIOTECHDS
 1 FILE CAPLUS
 27 FILES SEARCHED...
 12 FILE IFIPAT
 48 FILES SEARCHED...
 14 FILE USPATFULL
 1 FILE USPAT2
 2 FILE WPIDS
 2 FILE WPINDEX

8 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L6 QUE ERYTHROPOIETIN WITH ADMINISTERING

=> d rank

F1 14 USPATFULL
 F2 12 IFIPAT
 F3 2 BIOTECHABS
 F4 2 BIOTECHDS
 F5 2 WPIDS
 F6 2 WPINDEX
 F7 1 CAPLUS
 F8 1 USPAT2

=> file ifipat biotechaba wpids caplus

'BIOTECHABA' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):biotechabs

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.93	8.14

FILE 'IFIPAT' ENTERED AT 15:08:16 ON 19 JUL 2006
 COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'WPIDS' ENTERED AT 15:08:16 ON 19 JUL 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 15:08:16 ON 19 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> erythropoietin with administering
L7 15 ERYTHROPOIETIN WITH ADMINISTERING

=> dup remove l7
PROCESSING COMPLETED FOR L7
L8 14 DUP REMOVE L7 (1 DUPLICATE REMOVED)

=> d ti 1-14

L8 ANSWER 1 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ERYTHROPOIETIN PRODUCTION ACCELERATOR

L8 ANSWER 2 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN DUPLICATE 1
TI METHOD FOR THE PRODUCTION OF AN ERYTHROPOIETIN ANALOG-HUMAN IGG FUSION
PROTEINS IN TRANSGENIC MAMMAL MILK

L8 ANSWER 3 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI COMBINATION DOSING REGIMEN FOR ERYTHROPOIETIN

L8 ANSWER 4 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION

L8 ANSWER 5 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES

L8 ANSWER 6 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION; ERYTHROPOIETIN
ANALOG-HUMAN SERUM ALBUMIN (EPOA-HSA) CHIMERIC PROTEIN COMPRISING DELETED
SITE FOR GLYCOSYLATION FOR TREATING PATIENT SUFFERING FROM ANEMIA
ASSOCIATED WITH RENAL FAILURE, VIRAL INFECTION, BLOOD LOSS OR CANCER

L8 ANSWER 7 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ERYTHROPOIETIN PRODUCTION POTENTIATOR

L8 ANSWER 8 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI RECOMBINANT HUMAN ERYTHROPOIETIN WITH ADVANTAGEOUS GLYCOSYLATION PROFILE;
DIAGNOSING ANEMIA

L8 ANSWER 9 OF 14 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
TI Producing erythropoietin useful in treating anemia or Crohn's disease,
involves contacting cells in culture with erythropoietin production
induction peptide such as poly-D-glutamic acid, and harvesting
erythropoietin from cells.

L8 ANSWER 10 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI METHOD OF TREATING ANEMIA CAUSED BY RIBAVIRIN TREATMENT OF HEPATITIS C
USING ERYTHROPOIETIN ALPHA; ADMINISTERING
ERYTHROPOIETIN OR A VECTOR THAT EXPRESSES EPO IN VIVO, CONCOMITANTLY OR
SEQUENTIALLY OR VIA CO- ADMINISTRATION WITH THE RBV OR WITH THE RBV AND
IFN.

L8 ANSWER 11 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ASIALOCYTOTOKINES AND TREATMENT OF LIVER DISEASE; ADMINISTERING AN
ASIALOINTERFERON; TARGETING A GLYCOPROTEIN TO A HEPATOCYTE BY CONTACTING
THE CELL WITH AN ASIALOGLYCOPROTEIN PRODUCED BY REMOVING SIALIC ACID
RESIDUES FROM A GLYCOPROTEIN

L8 ANSWER 12 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
TI ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION; ALSO NUCLEIC ACIDS

WHICH ENCODE EPOA-HSA FUSION PROTEINS

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Saving erythropoietin by administering L-carnitine?

L8 ANSWER 14 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
 TI ENHANCER FOR THE ANTIANEMIA EFFECT OF ERYTHROPOIETIN AND METHOD OF
 AUGMENTING THE ANTIANEMIA EFFECT OF ERYTHROPOIETIN

=> d ab bib 1, 2, 3, 7, 10, 13, 11

L8 ANSWER 1 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
 AB The present invention relates to a preventive or therapeutic agent for
 pathological conditions caused by reduced production of erythropoietin,
 or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or
 pure red cell aplasia, the agent comprising, as an active ingredient, a
 cyclic amine compound represented by the following formula (1):

D R A W I N G

wherein, R1, R2 and R3 each independently represent a hydrogen atom, a
 halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy,
 alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; W1 and W2 each
 independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4
 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl,
 substituted or unsubstituted aryl, substituted or unsubstituted
 heteroaryl, substituted or unsubstituted aralkyl, or substituted or
 unsubstituted heteroaralkyl group; and l, m and n each represents a
 number of 0 or 1, or a salt thereof or a solvate thereof.

AN 11091979 IFIPAT;IFIUDB;IFICDB
 TI ERYTHROPOIETIN PRODUCTION ACCELERATOR
 INF Dol; Takeshi, Tokyo, JP
 Imagawa; Shigehiko, Tsukuba-Shi, JP
 Ohkuchi; Masao, Tokorozawa-shi, JP
 Tamura; Masahiro, Tokyo, JP
 IN Dol Takeshi (JP); Imagawa Shigehiko (JP); Ohkuchi Masao (JP); Tamura
 Masahiro (JP)
 PAF Kowa Co., Ltd., Aichi, JP
 PA Kowa Co Ltd JP (46851)
 AG OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET,
 ALEXANDRIA, VA, 22314, US
 PI US 2006040986 A1 20060223
 AI US 2003-537407 20031205
 WO 2003-JP15589 20031205
 20050602 PCT 371 date
 20050602 PCT 102(e) date
 PRAI US 2002-431234P 20021206 (Provisional)
 FI US 2006040986 20060223
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 45
 GI 6 Figure(s).

FIG. 1 is a view showing the effect of addition of medicaments on the
 amount of a EPO protein produced by Hep3B cells under 1% O2.
 FIG. 2 is a view showing the effect of addition of medicaments on the
 activity of EPO promotor.
 FIG. 3 is a view showing the effect of addition of medicaments on Ht value
 in anemia model mice.
 FIG. 4 is a view showing the effect of addition of medicaments on Hb
 amount in anemia model mice.
 FIG. 5 is a view showing the effect of addition of medicaments on the
 number of reticulocytes in anemia model mice.

FIG. 6 is a view showing the effect of addition of medicaments on the EPO amount in blood serum.

L8 ANSWER 2 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN DUPLICATE 1
AB Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein.
AN 10942750 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR THE PRODUCTION OF AN ERYTHROPOIETIN ANALOG-HUMAN IGG FUSION PROTEINS IN TRANSGENIC MAMMAL MILK
INF Krane; Ian, Westboro, MA, US
Meade; Harry M., Newton, MA, US
IN Krane Ian; Meade Harry M
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
PPA GTC BIOTHERAPEUTICS INC (Probable)
AG GTC BIOTHERAPEUTICS, INC., 175 CROSSING BOULEVARD, SUITE 410, FRAMINGHAM, MA, 01702, US
PI US 2005181482 A1 20050818
AI US 2005-49853 20050203
PRAI US 2004-543900P 20040212 (Provisional)
FI US 2005181482 20050818
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION
CLMN 61

L8 ANSWER 3 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
AB The present invention provides a combination dosing regimen for erythropoietin (EPO). More particularly, the present dosing regimen includes administration of at least a first dosing segment comprising a first exposure to EPO capable of stimulating the production of reticulocytes followed by a second exposure to EPO capable of sustaining the maturation of the reticulocytes into neocytes, and ultimately, red blood cells. Advantageously, the dosing segment may be cycled or repeated, any number of times and according to any desired time scheme, in order to provide or maintain any desired total red blood cell count and/or hemoglobin concentration. Methods of treatment employing the combination dosing regimen, as well as kits are also provided.
AN 11028278 IFIPAT;IFIUDB;IFICDB
TI COMBINATION DOSING REGIMEN FOR ERYTHROPOIETIN
INF Cheung; Wing K., Warren, NJ, US
IN Cheung Wing K
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG PHILIP S. JOHNSON;JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
PI US 2005267026 A1 20051201
AI US 2005-88284 20050324
PRAI US 2004-556923P 20040326 (Provisional)
FI US 2005267026 20051201
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION
PARN This Application claims priority from U.S. Provisional Application No. 60/556,923 entitled "Combination dosing regimen for erythropoietin" the contents of which are hereby incorporated by reference in their entirety.
CLMN 40

L8 ANSWER 7 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
AB A method for treating a pathological condition caused by reduced production of erythropoietin. The method includes administering to a subject an effective amount of N,N'-bis(5(3,4,5-trimethoxyphenyl)-4-pentenyl)homopiperazine, an acid-addition salt thereof, a hydrate of N,N'-bis(5-(3,4,5-trimethoxyphenyl)4-pentenyl)homopiperazine, or a

hydrate of the salt.

AN 10546700 IFIPAT;IFIUDB;IFICDB
TI ERYTHROPOIETIN PRODUCTION POTENTIATOR
INF Doi; Takeshi, Tokyo, JP
Imagawa; Shigehiko, Tsukuba-shi, JP
IN Doi Takeshi (JP); Imagawa Shigehiko (JP)
PAF KOWA CO., LTD., Aichi, JP
PA Kowa Co Ltd JP (46851)
AG OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US
PI US 2004053918 A1 20040318
AI US 2003-607996 20030630
PRAI US 2002-391952P 20020628 (Provisional)
FI US 2004053918 20040318
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
PARN This application claims priority to U.S. Provisional Application No.
60/391,952, filed Jun. 28, 2002, the contents of which are hereby
incorporated by reference in their entirety.

CLMN 20
GI 3 Figure(s).
FIG. 1 shows effect of compound 1 on the amount of EPO produced by Hep3B
cells under 21% O₂;
FIG. 2 shows effect of compound 1 on the amount of EPO produced by Hep3B
cells under 1% O₂; and
FIG. 3 shows effect of L-NMMA or compound 1 on EPO potentiator activity.

L8 ANSWER 10 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
AB Claimed and disclosed in a new use for a previously approved drug:
erythropoietin. The present invention teaches using Erythropoietin to
treat anemia caused by the combined treatment of Ribavirin and
alpha-interferon. Erythropoietin has previously been approved for the
treatment of anemia caused by cancer chemotherapy, renal failure and HIV.
It has not been used for anemia caused by ribavirin. Ribavirin is part of
a two-drug regimen now used to treat hepatitis C along with alpha
interferon. The principal side effect of ribavirin is a hemolytic anemia.
In the past, management of that anemia was done by dose reduction of the
ribavirin, sometimes resulting in reversal of part of the anemia. It has
become particularly important in light of new data, to maximize the dose
of ribavirin given to persons undergoing treatment for hepatitis C to
ensure a successful eradication of hepatitis C.

AN 10288182 IFIPAT;IFIUDB;IFICDB
TI METHOD OF TREATING ANEMIA CAUSED BY RIBAVIRIN TREATMENT OF HEPATITIS C
USING ERYTHROPOIETIN ALPHA; ADMINISTERING
ERYTHROPOETIN OR A VECTOR THAT EXPRESSES EPO IN VIVO, CONCOMITANTLY OR
SEQUENTIALLY OR VIA CO- ADMINISTRATION WITH THE RBV OR WITH THE RBV AND
IFN.
INF Dieterich; Douglas T., Garden City, NY, US
IN Dieterich Douglas T
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE-10TH FL., NEW YORK, NY, 10151,
US
PI US 2003032590 A1 20030213
AI US 2001-862404 20010521
FI US 2003032590 20030213
US 6833351 20041221
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 138:148137
CLMN 16
GI 19 Figure(s).

FIG. 1 shows a study design and results thereof for administering EPO with RBV and/or IFN-alpha .
 FIG. 2 shows a collection of plots of hemoglobin levels by time for 18 EPO-treated patients. FIG. 2.1 represents Subject #2;
 FIG. 2.2 represents Subject #3;
 FIG. 2.3 represents Subject #4;
 FIG. 2.4 represents Subject #5;
 FIG. 2.5 represents Subject #6;
 FIG. 2.6 represents Subject #7;
 FIG. 2.7 represents Subject #8;
 FIG. 2.8 represents Subject #11;
 FIG. 2.9 represents Subject #13;
 FIG. 2.10 represents Subject #14;
 FIG. 2.11 represents Subject #15;
 FIG. 2.12 represents Subject #16;
 FIG. 2.13 represents Subject #18;
 FIG. 2.14 represents Subject #19;
 FIG. 2.15 represents Subject #20;
 FIG. 2.16 represents Subject #21;
 FIG. 2.17 represents Subject #22; and
 FIG. 2.18 represents Subject #23.

L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AB A review with 28 refs. on the use of L-carnitine as a replacement for erythropoietin for correction of anemia in patients with end-stage renal disease. A consensus group concluded that routine administration of carnitine cannot be recommended in dialysis patients today.
 AN 2000:24626 CAPLUS
 DN 132:58620
 TI Saving erythropoietin by administering L-carnitine?
 AU Bommer, Jurgan
 CS Nephrology Department, Universitatsklinik Heidelberg, Heidelberg, D-69115, Germany
 SO Nephrology, Dialysis, Transplantation (1999), 14(12), 2819-2821
 CODEN: NDTREA; ISSN: 0931-0509
 PB Oxford University Press
 DT Journal; General Review
 LA English
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 14 IFIPAT COPYRIGHT 2006 IFI on STN
 AB The invention features methods for treating liver disease (e.g., viral hepatitis) by administering an asialocytokine (e.g., asialointerferon). The invention also includes methods of targeting a glycoprotein to a hepatocyte and a composition containing an asialocytokine.
 AN 10243417 IFIPAT;IFIUDB;IFICDB
 TI ASIALOCYTOKINES AND TREATMENT OF LIVER DISEASE; ADMINISTERING AN ASIALOINTERFERON; TARGETING A GLYCOPROTEIN TO A HEPATOCYTE BY CONTACTING THE CELL WITH AN ASIALOGLYCOPROTEIN PRODUCED BY REMOVING SIALIC ACID RESIDUES FROM A GLYCOPROTEIN
 INF Takahashi; Hiroshi, Boston, MA, US
 IN Takahashi Hiroshi
 PAF The General Hospital Corporation, a Massachusetts corporation
 PA General Hospital Corp The (10301)
 AG ANITA L. MEIKLEJOHN, PH.D. Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804, US
 PI US 2002187124 A1 20021212
 AI US 2002-113306 20020329
 RLI US 1996-721828 19960927 CONTINUATION-IN-PART ABANDONED
 US 1999-302765 19990430 DIVISION 6296844
 US 2001-969225 20011002 DIVISION PENDING
 PRAI US 1995-4357P 19950927 (Provisional)
 FI US 2002187124 20021212

US 6296844

DT Utility; Patent Application - First Publication
00001000

**

FS CHEMICAL
APPLICATION

GOVI (0002) This invention was made with government support under National Institutes of Health grants CA57584 and NIDDK4331. The Government has certain right in the invention.

CLMN 27

GI 11 Figure(s).

FIG. 1 is a graph depicting the results of an analysis of serum HBeAg level (open symbols) and anti-HBe antibody titer (closed symbols) in rats transfected with pHBV-HTD (circles) or pGEM7Zf(+) (triangles). The relative concentrations of HBeAg and anti-HBe are given by A492 and percent inhibition, respectively, as described herein. Specimens whose A492 value is equal to or greater than the cutoff value of 0.065 (mean of the negative control plus the factor 0.06) are considered to be positive for HBeAg, and those with a percent inhibition value equal to or greater than 50% are considered to be positive for anti-HBe.

FIG. 2 is a graph illustrating serum GOT levels in normal CD rats (o) and in athymic nude rats (*) transfected with pHBV-HTD.

FIG. 3 is a schematic illustration of the structure of natural human IFN-beta. Also illustrated are the cleavage sites of typical biantennary complex-type sugar chains of natural human IFN-beta by neuraminidase. Abbreviations: Fuc, fucose; GlcNAc, N-acetylglucosamine; Man, mannose; Gal, galactose; NeuAc, N-acetylneuraminic acid.

FIG. 4 is a graph of a standard curve for the quantification of HBV DNA by radioactive PCR using (alpha-33P)-dCTP.

FIG. 5 is a graph of HBV copy number in a culture of HBV DNA-transfected Hep G2 cells versus interferon concentration in the culture media. HBV-transfected Hep G2 cells were treated with human natural IFN-alpha, human natural IFN-beta, or asialoIFN-beta (at 10, 100, or 1000 IU/ml) every 24 hours for 48 hours. The reduced production of HBV in the culture supernatant of transfected Hep G2 cells is shown by the reduction in copy number of HBV DNA-containing virions that are present in one milliliter of the culture supernatant. Results are the mean plus or minus one standard deviation (SD) or values obtained in triplicate experiments.

FIG. 5 is a graph of OD590 in a cell viability assay using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) versus time. Hep G2 cells were treated with 1000 IU/ml of conventional IFN-alpha, IFN-beta, or asialo-IFN-beta every 24 hours for 72 hours. Results are the mean plus or minus SD of values obtained in triplicate experiments.

FIG. 7 is a bar graph of HBV copy number in untreated ASGP receptor-negative liver cells or the same cells treated with IFN-alpha, IFN-beta, or asialo-IFN-beta. SK-HEP-1 cells were treated with 1000 IU/ml of cytokine every 24 hours for 48 hours. Results are the mean plus or minus SD of values obtained in triplicate assays.

FIG. 3 is a bar graph of HBV copy number in cells treated with various concentrations of asialo-IFN-beta and/or asialofetuin, a competitor for the ASGP receptor. HBV DNA-transfected Hep G2 cells were treated every 24 hours for 48 hours with 100 IU/ml of asialo-IFN-beta in the presence of various concentrations of asialofetuin (0-1.0 micromolar). Results are the mean plus or minus SD of values obtained in triplicate experiments.

FIG. 9 is bar graph of HBV copy number in cell cultures treated with asialo-IFN-beta, non-specific mouse TgG1/kappa, or a mouse antibody which neutralizes human IFN-beta (B-02, IgG1/kappa, Japan Immuno-Monitoring Center, Inc., Tokyo, Japan). HBV DNA-transfected Hep G2 cells were treated every 24 hours for 48 hours with 100 IU/ml of asialo-IFN-beta in the presence of one microgram/ml of B-02 antibody or non-specific mouse antibody. Results are the mean plus or minus SD of values obtained in triplicate experiments.

FIG. 10 is a plot of the relative change in serum HBV virion levels in HBV-transfected mice for various treatments.

FIG. 11 is a graph of 2-5A synthetase activity in a cell culture versus number of hours of IFN treatment. The open circles represent the level of 2-5A synthetase during native IFN-beta treatment. The closed circles represent the level of 2-5A synthetase during asialo-IFN-beta treatment.